ETF

Three Stocks Are Joining the S&P 500. Will They Actually Improve VOO’s Returns?

Three new names are entering the S&P 500, swapping out brewers and homebuilders for fuel-cell technology and genomics, but whether that trade actually benefits VOO holders depends on a math problem most investors overlook.

Published September 16, 2026, 11:55am ET · 3 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

A blurred digital display lists U.S. stock market indices: Dow Jones, S&P 500, NASDAQ 100, and Russell 2000, each with an American flag next to its name. Green upward arrows indicate positive movement, with corresponding white, blurred numerical values. The screen background is dark.
A digital display shows major U.S. stock market indices, including the S&P 500, with positive gains indicated by green arrows. This visual reflects the broader market sentiment as key benchmarks experience adjustments. © bopav / iStock via Getty Images

Before trading opens on September 21, 2026, the Vanguard S&P 500 ETF (NYSEARCA:VOO) will rebuild a sliver of its index exposure, according to S&P Dow Jones Indices. S&P Dow Jones Indices announced on September 4, 2026, that three companies are joining the benchmark: Bloom Energy (NYSE:BE) and Illumina (NASDAQ:ILMN | ILMN Price Prediction). Making room, three names leave: Molson Coors (NYSE:TAP), The Trade Desk (NASDAQ:TTD), and Builders FirstSource (NYSE:BLDR).

For a VOO holder, the swap changes the story of your fund far more than its returns, because VOO uses full replication of a float-adjusted, cap-weighted benchmark, and none of the six names come close to the megacaps that drive performance.

What the Swap Actually Changes

You are trading a struggling brewer, an ad-tech platform in growth decline, and a homebuilder in a housing downcycle for a fuel-cell company riding AI power demand, a sequencing leader, and a water-treatment business.

Bloom Energy arrives on a tear. Product revenue jumped 215% last quarter as hyperscalers bought onsite fuel-cell capacity, and CEO KR Sridhar told investors, “Bloom is now a standard for AI onsite power.” Management raised full-year revenue guidance to $3.9 billion to $4.2 billion.

Illumina brings clinical sequencing back into the index after a bruising few years, with revenue up 9% in the second quarter and raised EPS guidance of $5.30 to $5.40. Service and other revenue climbed as NovaSeq X adoption deepened, and management pointed to building momentum through the first half of 2026 despite ongoing China and tariff headwinds.

Why the Weights Barely Move the Needle

Vanguard’s factsheet, dated June 30, 2026, showed 38% of VOO in its ten largest holdings, including 8% in NVIDIA (NASDAQ:NVDA) alone. S&P 500 entrants typically begin well under a tenth of a percent of the index. A 0.1% starting position that doubles would contribute roughly 0.1 percentage point to total return if everything else were unchanged, before trading and tracking costs.

Membership changes rarely register in a broad-market index fund’s annual return. The megacap tilt at the top does the heavy lifting. VOO’s 0.03% expense ratio and cap-weighted mechanics matter more than any single admission.

Growth Coming In, Cyclicals Going Out

The composition change shifts the index’s flavor at the margin. Bloom carries a beta of 3.81 and a forward P/E of 57x, while Illumina trades at a forward P/E of 34x.

The departures are the opposite. Molson Coors trades at a forward P/E of 7x with a 4.9% dividend yield, and Builders FirstSource trades at a forward P/E of 14x. You are paying up for AI and healthcare growth and giving up cheap cyclical and defensive names near cycle lows.

The Bull and Bear Case for VOO

The bull case for VOO is unchanged by this rebalance. You hold the broad U.S. market at fractional cost, and the S&P committee automatically refreshes the roster toward businesses meeting scale, profitability, and liquidity screens. VOO returned 16% over the past year and 317% over ten years.

The bear case is concentration risk that no rebalance can fix. With Vanguard’s factsheet showing 38% in ten names and 8% in a single AI chipmaker, VOO’s next drawdown will likely be dictated by megacap tech multiples, although Bloom’s 3.81 beta will amplify moves in its small slice.

What decides VOO’s next year is whether the index top keeps delivering the earnings growth its current multiples require.

Contact [email protected] for any questions or corrections.

Omor Ibne Ehsan

Omor Ibne Ehsan is a writer at 24/7 Wall St. He is a self-taught investor with a focus on growth, cyclical, and dividend equities that have strong fundamentals, value, and long-term potential. He also has an interest in high-risk, high-reward investments such as penny stocks.

All articles →